Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Announces its 2025 Financial Calendar

Mauna Kea Technologies Announces its 2025 Financial Calendar